Roth Capital Starts Cerulean Pharma (CERU) at Buy, $9 PT

Roth Capital initiates coverage on Cerulean Pharma (NASDAQ: CERU) with a Buy rating and a price target of $9.00.

Analyst Debjit Chattopadhyay commented, "We initiate Cerulean with a Buy rating and $9 target. Over the past few months Cerulean has significantly under-performed its peers due to lack of near-term catalysts, and investor attention that has been primarily focused on the expanding reach of immune-oncology. We are positively biased on the outcome of the upcoming mid-stage, randomized study readout, which should alter investor sentiment and validate Cerulean's tumor-targeted nanoparticle platform technology, that has a significant role to play in late-stage cancer treatment, in our view."

For an analyst ratings summary and ratings history on Cerulean Pharma click here. For more ratings news on Cerulean Pharma click here.

Shares of Cerulean Pharma closed at $3.53 yesterday.

You May Also Be Interested In

• Cleveland Research Upgrades Dynatrace Inc. (DT) to Buy, 'optimism underlying fundamentals are likely to support upside'
• Rentokil Initial (RTO) PT Lowered to $35 at Oppenheimer
• Badger Meter (BMI) PT Raised to $175 at Stifel